US Stock MarketDetailed Quotes

IKT Inhibikase Therapeutics

Watchlist
  • 1.3600
  • -0.0400-2.86%
Close May 9 16:00 ET
  • 1.3400
  • -0.0200-1.47%
Post 19:23 ET
8.81MMarket Cap-380P/E (TTM)

Inhibikase Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Inhibikase Therapeutics Earnings Date

Currency: USD

Period

Q4 FY2023 Earnings

Mar 28, 2024

Revenue(YoY)

1.00

-100.00%
EPS(YoY)

-0.64

+37.25%
Analyst Rating

Buy

Apr 30, 2024

Inhibikase Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q2-- / 0.000--
--2024/Q1-- / 0.000--
Mar 28, 20242023/Q40.000 / 0.000--
Nov 14, 20232023/Q379.570K / 0.000--
Aug 14, 20232023/Q2116.410K / 0.000--
May 15, 20232023/Q164.520K / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q2-- / 0.000--
--2024/Q1-- / 0.000--
Mar 28, 20242023/Q40.000 / 0.000--
Nov 14, 20232023/Q379.570K / 0.000--
Aug 14, 20232023/Q2116.410K / 0.000--
May 15, 20232023/Q164.520K / 0.000--
--------
--------
--------
--------

Unlock Free Earnings Estimates

Inhibikase Therapeutics Earnings Reports

  • Inhibikase Therapeutics | 10-K: Annual report

    Mar 28 04:12

  • Inhibikase Therapeutics: Q3 2023 Earnings Report

    Nov 15, 2023 05:15

  • Inhibikase Therapeutics | 10-K/A: Annual report (Amendment)

    Oct 17, 2023 05:24

  • Inhibikase Therapeutics | 10-Q: Q2 2023 Earnings Report

    Aug 15, 2023 04:07

    • Read more

    Analysis

    Analyst Rating

    Updated: Apr 30, 2024

    Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg
    Concept Top Gainers Yesterday
    Top Gainers Yesterday
    Intraday+0.54%